Shield Therapeutics announces review of the marketing authorisation application for Feraccru®

Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals, announced the recent acceptance for review by the European Medicines Agency (EMA) of the marketing authorisation application (MAA) for Feraccru (ST10, ferric maltol).

Source: Pharmacy Europe - January 7, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Haematology Policy practice anaemia feraccru ferric maltol haemoglobin hospital pharmaceuticals Latest News Source Type: news